Cargando…

Long-Term Biocompatibility of a Highly Viscously Thiol-Modified Cross-Linked Hyaluronate as a Novel Vitreous Body Substitute

Purpose: In surgical ophthalmology, the treatment of complicated retinal and vitreous diseases is one of the central challenges. For this purpose, the vitreous body is removed as part of the standard therapy and replaced by a temporary tamponade to stabilize the position of the retina. Since the tam...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurst, Jose, Rickmann, Annekatrin, Heider, Nele, Hohenadl, Christine, Reither, Charlotte, Schatz, Andreas, Schnichels, Sven, Januschowski, Kai, Spitzer, Martin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924550/
https://www.ncbi.nlm.nih.gov/pubmed/35308238
http://dx.doi.org/10.3389/fphar.2022.817353
_version_ 1784669882449657856
author Hurst, Jose
Rickmann, Annekatrin
Heider, Nele
Hohenadl, Christine
Reither, Charlotte
Schatz, Andreas
Schnichels, Sven
Januschowski, Kai
Spitzer, Martin S.
author_facet Hurst, Jose
Rickmann, Annekatrin
Heider, Nele
Hohenadl, Christine
Reither, Charlotte
Schatz, Andreas
Schnichels, Sven
Januschowski, Kai
Spitzer, Martin S.
author_sort Hurst, Jose
collection PubMed
description Purpose: In surgical ophthalmology, the treatment of complicated retinal and vitreous diseases is one of the central challenges. For this purpose, the vitreous body is removed as part of the standard therapy and replaced by a temporary tamponade to stabilize the position of the retina. Since the tamponading properties of previous materials such as silicone oils, gases, or semi-fluorinated alkanes are a combination of their surface tension and their buoyancy vector, they cannot completely fill the vitreous cavity. The aim of this work was to test in vivo a novel vitreous body substitute (ViBos strong) based on cross-linked hyaluronic acid for its compatibility. Methods: A pars plana vitrectomy with posterior vitreous detachment was performed in the right eye of 18 pigmented rabbits, with subsequent injection of ViBos strong. Follow-up examination included slit-lamp examination, funduscopy, intraocular pressure measurements (IOP), optical coherence tomography (OCT), and electroretinogram (ERG) measurements. The rabbits were sacrificed at three different time points (1, 3, and 6 months; each 6 animals) and examined macroscopically and prepared for histological examination (HE staining) and immunohistochemistry (Brn3a and glial fibrillary acidic protein (GFAP)). Results: ViBos strong demonstrated good intraoperative handling and remained stable for at least 1 month and degraded slowly over 6 months. IOP was within clinical acceptable values at all follow-up examinations. Retinal function was well preserved after instillation of the hydrogel and comparable to the untreated eye after 6 months in OCT, ERG, and histological examinations. An increase in the GFAP expression was found in the surgery eyes, with a peak in the 3-month group. The Brn3a expression was not significantly affected by vitrectomy with ViBos strong. Conclusion: Highly viscously thiol-modified cross-linked hyaluronate showed a good biocompatibility in rabbit eyes over 6 months after vitrectomy, making it a promising potential as a vitreous substitute.
format Online
Article
Text
id pubmed-8924550
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89245502022-03-17 Long-Term Biocompatibility of a Highly Viscously Thiol-Modified Cross-Linked Hyaluronate as a Novel Vitreous Body Substitute Hurst, Jose Rickmann, Annekatrin Heider, Nele Hohenadl, Christine Reither, Charlotte Schatz, Andreas Schnichels, Sven Januschowski, Kai Spitzer, Martin S. Front Pharmacol Pharmacology Purpose: In surgical ophthalmology, the treatment of complicated retinal and vitreous diseases is one of the central challenges. For this purpose, the vitreous body is removed as part of the standard therapy and replaced by a temporary tamponade to stabilize the position of the retina. Since the tamponading properties of previous materials such as silicone oils, gases, or semi-fluorinated alkanes are a combination of their surface tension and their buoyancy vector, they cannot completely fill the vitreous cavity. The aim of this work was to test in vivo a novel vitreous body substitute (ViBos strong) based on cross-linked hyaluronic acid for its compatibility. Methods: A pars plana vitrectomy with posterior vitreous detachment was performed in the right eye of 18 pigmented rabbits, with subsequent injection of ViBos strong. Follow-up examination included slit-lamp examination, funduscopy, intraocular pressure measurements (IOP), optical coherence tomography (OCT), and electroretinogram (ERG) measurements. The rabbits were sacrificed at three different time points (1, 3, and 6 months; each 6 animals) and examined macroscopically and prepared for histological examination (HE staining) and immunohistochemistry (Brn3a and glial fibrillary acidic protein (GFAP)). Results: ViBos strong demonstrated good intraoperative handling and remained stable for at least 1 month and degraded slowly over 6 months. IOP was within clinical acceptable values at all follow-up examinations. Retinal function was well preserved after instillation of the hydrogel and comparable to the untreated eye after 6 months in OCT, ERG, and histological examinations. An increase in the GFAP expression was found in the surgery eyes, with a peak in the 3-month group. The Brn3a expression was not significantly affected by vitrectomy with ViBos strong. Conclusion: Highly viscously thiol-modified cross-linked hyaluronate showed a good biocompatibility in rabbit eyes over 6 months after vitrectomy, making it a promising potential as a vitreous substitute. Frontiers Media S.A. 2022-03-02 /pmc/articles/PMC8924550/ /pubmed/35308238 http://dx.doi.org/10.3389/fphar.2022.817353 Text en Copyright © 2022 Hurst, Rickmann, Heider, Hohenadl, Reither, Schatz, Schnichels, Januschowski and Spitzer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Hurst, Jose
Rickmann, Annekatrin
Heider, Nele
Hohenadl, Christine
Reither, Charlotte
Schatz, Andreas
Schnichels, Sven
Januschowski, Kai
Spitzer, Martin S.
Long-Term Biocompatibility of a Highly Viscously Thiol-Modified Cross-Linked Hyaluronate as a Novel Vitreous Body Substitute
title Long-Term Biocompatibility of a Highly Viscously Thiol-Modified Cross-Linked Hyaluronate as a Novel Vitreous Body Substitute
title_full Long-Term Biocompatibility of a Highly Viscously Thiol-Modified Cross-Linked Hyaluronate as a Novel Vitreous Body Substitute
title_fullStr Long-Term Biocompatibility of a Highly Viscously Thiol-Modified Cross-Linked Hyaluronate as a Novel Vitreous Body Substitute
title_full_unstemmed Long-Term Biocompatibility of a Highly Viscously Thiol-Modified Cross-Linked Hyaluronate as a Novel Vitreous Body Substitute
title_short Long-Term Biocompatibility of a Highly Viscously Thiol-Modified Cross-Linked Hyaluronate as a Novel Vitreous Body Substitute
title_sort long-term biocompatibility of a highly viscously thiol-modified cross-linked hyaluronate as a novel vitreous body substitute
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924550/
https://www.ncbi.nlm.nih.gov/pubmed/35308238
http://dx.doi.org/10.3389/fphar.2022.817353
work_keys_str_mv AT hurstjose longtermbiocompatibilityofahighlyviscouslythiolmodifiedcrosslinkedhyaluronateasanovelvitreousbodysubstitute
AT rickmannannekatrin longtermbiocompatibilityofahighlyviscouslythiolmodifiedcrosslinkedhyaluronateasanovelvitreousbodysubstitute
AT heidernele longtermbiocompatibilityofahighlyviscouslythiolmodifiedcrosslinkedhyaluronateasanovelvitreousbodysubstitute
AT hohenadlchristine longtermbiocompatibilityofahighlyviscouslythiolmodifiedcrosslinkedhyaluronateasanovelvitreousbodysubstitute
AT reithercharlotte longtermbiocompatibilityofahighlyviscouslythiolmodifiedcrosslinkedhyaluronateasanovelvitreousbodysubstitute
AT schatzandreas longtermbiocompatibilityofahighlyviscouslythiolmodifiedcrosslinkedhyaluronateasanovelvitreousbodysubstitute
AT schnichelssven longtermbiocompatibilityofahighlyviscouslythiolmodifiedcrosslinkedhyaluronateasanovelvitreousbodysubstitute
AT januschowskikai longtermbiocompatibilityofahighlyviscouslythiolmodifiedcrosslinkedhyaluronateasanovelvitreousbodysubstitute
AT spitzermartins longtermbiocompatibilityofahighlyviscouslythiolmodifiedcrosslinkedhyaluronateasanovelvitreousbodysubstitute